Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 3, 2007

Panagene Secures License to Commercialize PNA Monomers

  • Panagene licensed the right to sell PNA monomers from the Copenhagen Inventor Group (CIG). The company will synthesize, manufacture, and sell peptide nucleic acids (PNA) monomers.

    Panagene previously obtained exclusive, worldwide license under CIG's patents to PNA custom synthesis. "This license from CIG, in addition to the custom PNA synthesis license already granted, shows our continued commitment to expand the field of PNA research," says Sung Kee Kim, Ph.D., president and CEO of Panagene.

    Panagene estimates the PNA market today to be approximately 5% of the DNA/RNA synthesis market but believes that this license will help it grow the business.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »